Rezolute's Phase 3 sunRIZE study of ersodetug gets positive DMC recommendation; enrollment May, data Dec 2025

Rezolute, Inc.

Independent DMC recommends continuation of sunRIZE study as planned; no need to increase sample size.
Enrollment expected to complete in May 2025; topline data anticipated in December 2025.
U.S. sites now activated and enrolling; global study across more than a dozen countries.
Interim analysis evaluated primary endpoint of hypoglycemia events after ~50% of patients completed assessments.
Rezolute remains blinded to interim data; DMC recommendation based on pre-specified futility and sample size assessment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.